Evidence map›Paper›PMID 30664785›Full record

ArticleNature medicine2019

Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.

Morgan L Maeder, Michael Stefanidakis, Christopher J Wilson, Reshica Baral, Luis Alberto Barrera, George S Bounoutas, David Bumcrot, Hoson Chao, Dawn M Ciulla, Jennifer A DaSilva and 27 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 425 papers.

0numbers the graph read from it
0cells of the map it votes in
425citing papers in PubMed
34.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

425 citing papers in PubMed, 682 citations in OpenAlex.

  1. Gene Editing forThe New England journal of medicine · 2024
    Trial
  2. In vivo CRISPR gene editing in patients with herpetic stromal keratitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Trial
  3. CRISPR/Cas Systems: Biological Basis and Genome Editing Applications.Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. A primer on prime: A prime editing update from advances to first-in-human trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

365 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 2 institutions in 1 country.

Morgan L MaederEditas Medicine, Cambridge, MA, USA. morganLmaeder@gmail.com.ORCID http://orcid.org/0000-0001-9229-0479
Michael StefanidakisEditas Medicine, Cambridge, MA, USA.
Christopher J WilsonEditas Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9146-522X
Reshica BaralEditas Medicine, Cambridge, MA, USA.
Luis Alberto BarreraEditas Medicine, Cambridge, MA, USA.
George S BounoutasEditas Medicine, Cambridge, MA, USA.
David BumcrotEditas Medicine, Cambridge, MA, USA.
Hoson ChaoEditas Medicine, Cambridge, MA, USA.
Dawn M CiullaEditas Medicine, Cambridge, MA, USA.
Jennifer A DaSilvaEditas Medicine, Cambridge, MA, USA.
Abhishek DassEditas Medicine, Cambridge, MA, USA.
Vidya DhanapalEditas Medicine, Cambridge, MA, USA.
Tim J FennellFulcrum Genomics, Somerville, MA, USA.ORCID http://orcid.org/0000-0002-8521-1493
Ari E FriedlandEditas Medicine, Cambridge, MA, USA.
Georgia GiannoukosEditas Medicine, Cambridge, MA, USA.
Sebastian W GloskowskiEditas Medicine, Cambridge, MA, USA.
Alexandra GlucksmannEditas Medicine, Cambridge, MA, USA.
Gregory M GottaEditas Medicine, Cambridge, MA, USA.
Hariharan JayaramEditas Medicine, Cambridge, MA, USA.
Scott J HaskettEditas Medicine, Cambridge, MA, USA.
Bei HopkinsEditas Medicine, Cambridge, MA, USA.
Joy E HorngEditas Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7702-7381
Shivangi JoshiEditas Medicine, Cambridge, MA, USA.
Eugenio MarcoEditas Medicine, Cambridge, MA, USA.
Rina MepaniEditas Medicine, Cambridge, MA, USA.
Deepak ReyonEditas Medicine, Cambridge, MA, USA.
Terence TaEditas Medicine, Cambridge, MA, USA.
Diana G TabbaaEditas Medicine, Cambridge, MA, USA.
Steven J SamuelssonEditas Medicine, Cambridge, MA, USA.
Shen ShenEditas Medicine, Cambridge, MA, USA.
Maxwell N SkorEditas Medicine, Cambridge, MA, USA.
Pam StetkiewiczEditas Medicine, Cambridge, MA, USA.
Tongyao WangEditas Medicine, Cambridge, MA, USA.
Clifford YudkoffEditas Medicine, Cambridge, MA, USA.
Vic E MyerEditas Medicine, Cambridge, MA, USA.
Charles F AlbrightEditas Medicine, Cambridge, MA, USA.
Haiyan JiangEditas Medicine, Cambridge, MA, USA.
Editas Medicine (United States) · USFulcrum Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leber congenital amaurosis type 10 is a severe retinal dystrophy caused by mutations in the CEP290 gene

Indexed as

Gene EditingAnimalsCell LineGene Knock-In TechniquesHumansLeber Congenital AmaurosisMicePrimatesReproducibility of ResultsVision, Ocular

Identifiers

PMID30664785
OpenAlexW2908873329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.